PTC Therapeutics, Inc.
100 Corporate Court
326 articles with PTC Therapeutics, Inc.
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
Analysis of data to date shows Translarna Preserved Ambulation for up to 5 Years Compared to Natural History
Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients
Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones
PTC Therapeutics announced interim data from Part 1 of its open-label clinical trials, FIREFISH and SUNFISH, of risdiplam for Type 1, 2 and 3 spinal muscular atrophy in collaboration with Genentech.
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on September 25, 2018
PTC Therapeutics, Inc. today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.
PTC Therapeutics, Inc. today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, October 9th at 2:00 p.m. EST.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27th at 1:30 p.m. EST.
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
This week has several action dates by the U.S. Food and Drug Administration (FDA) for a range of indications, including acne, intra-abdominal infections, and rare liver diseases. Here’s a look.
PTC Therapeutics Reports Inducement Grants of 381,500 Shares of its Common Stock Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. today announced that on August 22, 2018 it approved non-statutory stock options to purchase an aggregate of 381,500 shares of its common stock to 15 new employees.
With the acquisition, PTC adds GT-AADC, an adeno-associated virus (AAV) gene therapy that treats Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
PTC Therapeutics, Inc. announced that on August 6, 2018 it approved non-statutory stock options to purchase an aggregate of 170,200 shares of its common stock to 27 new employees.
Entered into agreement to acquire Agilis Biotherapeutics
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America
PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea
Dedicated Online Platform DuchenneXchange.org Launches to Unite, Support and Educate Duchenne Community
The Duchenne muscular dystrophy (DMD) community now has a dedicated online platform where they can connect and share knowledge - DuchenneXchange (DuchenneXchange.org)
PTC Therapeutics, Inc. announced that the Company will host a webcast conference call to report its second quarter 2018 financial results and provide an update on the company's business and outlook on Tuesday, August 7, 2018 at 4:30 p.m. (ET) after closing of the market.
PTC Therapeutics Announces Publication of Data Demonstrating the Clinical Differentiated Benefit of Deflazacort
Post hoc analysis of the placebo arm of ACT DMD Data Published in Muscle & Nerve
PTC Therapeutics is buying Agilis Biotherapeutics in a deal that has the potential to exceed $945 million.
PTC Therapeutics, Inc., today announced that it has entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies.